Physician profile
Andy Chow
NPI 1336807288
$3,855.36
in general payments reported to CMS, 2019-2025
21 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $937 · 2024: $1,632 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,653 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,653.39 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,110.71 | 2023-2025 | |
| Janssen Biotech, INC. | $354.40 | 2023-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $333.66 | 2023-2025 | |
| Ardelyx, INC. | $309.46 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.24 | 2023-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $205.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $193.99 | 2023-2024 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $184.51 | 2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $156.33 | 2023-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $134.97 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2025 | Uzedy |
| Glaxosmithkline, LLC. | $124.98 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $100.61 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $91.37 | 2023-2024 | Dificid, Zinplava |
| Genzyme Corporation | $59.06 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $54.40 | 2024 | Sucraid |
| Aimmune Therapeutics, INC. | $27.34 | 2025 | Vowst |
| Pfizer INC. | $23.32 | 2025 | |
| Celgene Corporation | $18.00 | 2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $16.65 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $13.87 | 2023 | Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.